Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) belongs to Healthcare sector. Its weekly performance is -10.76%. On last trading day company shares ended up $12.61. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) distance from 50-day simple moving average (SMA50) is -25.37%. On 1 July, Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) announced that on June 30, 2015, the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 115,500 shares of common stock to four new employees, with all four grants having a grant date of June 30, 2015 (the “Q2 2015 Inducement Grants”).
Atlas Energy, L.P (NYSE:ATLS) shares fell -5.90% in last trading session and ended the day at $3.99. ATLS Gross Margin is 56.70% and its return on assets is -5.70%. Atlas Energy, L.P (NYSE:ATLS) quarterly performance is -40.80%. Analysts at Wells Fargo & Co. assumed coverage on shares of Atlas Energy, L.P (NYSE:ATLS) in a research report issued to clients and investors on Friday. The firm set a “market perform” rating on the stock
Groupon, Inc. (NASDAQ:GRPN) shares decreased -1.22% in last trading session and ended the day at $4.84. GRPN Gross Margin is 47.40% and its return on assets is -2.30%. Groupon, Inc. (NASDAQ:GRPN) quarterly performance is -34.42%. On 25 June, Groupon, Inc. (NASDAQ:GRPN) plans on hiring someone to do the easiest job in the world*. The job (that’s not actually a job) that we’ll hire for (not hire at all), requires this new employee (who is not employed by Groupon) to do nothing. Additionally that job (not a job) pays $100,000. Clear and simple.
On 10 July, NVIDIA Corporation (NASDAQ:NVDA) shares advanced 1.75% and was closed at $19.75. NVDA EPS growth in last 5 year was 62.50%. NVIDIA Corporation (NASDAQ:NVDA) year to date (YTD) performance is -0.66%. On 25 June, NVIDIA Corporation (NASDAQ:NVDA) said that, it will begin supplying hardware reference headers for the Nouveau DRM driver in a move that will see it catching up with AMD and Intel on supplying the steadily growing Linux gamer market.
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) ended the last trading day at $1.29. Company weekly volatility is calculated as 3.56% and price to cash ratio as 4.50. Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) showed a weekly performance of -0.77%.On 25 June, Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announced that the European Patent Office (EPO) has granted Patent Number 2,269,656, titled “Selected Antibodies Binding to Aminophospholipids and their Use in Treatment, Such as Cancer”. This important patent covers bavituximab as a composition of matter and for use in treating cancer including in combination with radiotherapy or chemotherapy, such as with docetaxel.